Canada Markets open in 3 hrs 46 mins


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.21000.0000 (0.00%)
At close: 03:38PM EST

H-CYTE, Inc.

2202 North West Shore Boulevard
Suite 200
Tampa, FL 33607
United States
888 664 2983

Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael W. YurkowskyCEO & Director180kN/A1972
Mr. Jeremy D. DanielChief Financial Officer200kN/A1976
Dr. Tanya Rhodes Ph.D.Chief Scientific Officer252kN/A1961
Mr. Jeffery Wright CPA, CPAController & Principal Accounting OfficerN/AN/A1983
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

Corporate Governance

H-CYTE, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.